US Patent 7,029,694: Oxybutynin Transdermal Gel Claims, Scope, Expiration and Patent Landscape

US Patent 7,029,694 protected a pharmacokinetic approach to transdermal oxybutynin therapy. Its central limitation was not merely the use of oxybutynin gel for overactive bladder. The claims required a defined plasma relationship between oxybutynin and its active metabolite, N-desethyloxybutynin, intended to reduce anticholinergic adverse effects associated with oral treatment.

The patent was granted on April 18, 2006. Its nominal 20-year patent term ran from the underlying nonprovisional filing date and appears to have ended in 2023, subject to any patent-term adjustment shown in the USPTO file. The patent therefore presents limited or no current US blocking risk if it has expired and no enforceable term extension applies. Its historical importance lies in the Gelnique oxybutynin gel patent estate and in the use of pharmacokinetic endpoints as claim limitations.

What does US Patent 7,029,694 cover?

The patent covers two related categories:

Methods of treating overactive bladder with topical oxybutynin gel.
Articles of manufacture consisting of an oxybutynin gel product having specified pharmacokinetic properties.

The independent claims are claims 1 and 15.

Claim	Type	Core subject matter
1	Method	Treating overactive bladder with topical oxybutynin gel while minimizing anticholinergic or antimuscarinic adverse experiences
15	Article of manufacture	Oxybutynin topical gel that produces the claimed oxybutynin-to-metabolite AUC ratio and minimizes adverse effects

The claims require a plasma AUC ratio of oxybutynin to an oxybutynin metabolite of approximately 0.5:1 to 5:1. Several dependent claims narrow the range, identify the metabolite, define stereochemistry, impose peak plasma concentration limits, or specify permeation enhancers.

The patent is therefore best characterized as a pharmacokinetic and delivery-system patent, rather than a basic oxybutynin compound patent.

What are the key limitations of claim 1?

Claim 1 requires each of the following elements:

A subject having overactive bladder.
Treatment with oxybutynin.
Administration as a topical gel.
A plasma AUC ratio of oxybutynin to an oxybutynin metabolite from approximately 0.5:1 to 5:1.
Treatment intended to minimize an anticholinergic or antimuscarinic adverse drug experience.
An optional permeation enhancer.

The practical infringement question is whether a competing topical product produces the claimed plasma exposure relationship when administered according to the product’s labeled or tested regimen.

The claim does not require:

A specific oxybutynin concentration in the gel.
A particular gel viscosity.
A specific permeation enhancer.
A particular application site.
A particular dosing frequency.
A particular commercial brand.
A racemic mixture, because dependent claims 31 to 33 separately cover the racemate and individual enantiomers.

The AUC ratio is the principal limiting feature. A topical oxybutynin product that does not produce the required ratio may fall outside claim 1 even if it treats overactive bladder and uses a gel.

How do the dependent claims narrow the patent scope?

The dependent claims create multiple overlapping claim positions.

Pharmacokinetic ratio limitations

Claims 2 and 3 narrow the overall oxybutynin-to-metabolite AUC ratio:

Claims	Ratio
1, 15	About 0.5:1 to 5:1
2, 16	About 1:1 to 5:1
3, 17	About 0.8:1 to 1.5:1
44	About 0.5:1 to 4:1
45	About 1:1 to 5:1
46	About 0.8:1 to 2.5:1

Claims 42 and 44 to 46 focus expressly on N-desethyloxybutynin. Claim 42 requires that the metabolite AUC not exceed the oxybutynin AUC by more than approximately 2:1.

Metabolite and stereochemistry limitations

Claims 5 and 19 identify the metabolite as N-desethyloxybutynin. Claims 6 and 20 cover the R enantiomer, the S enantiomer, or a combination.

Claims 4, 18, 31, 32, 33, 36, 37 and 38 address the oxybutynin stereoisomer:

R-oxybutynin
S-oxybutynin
A mixture of R- and S-oxybutynin

Claims 7, 8, 9, 10, 11, 21, 22, 23, 24 and 25 impose additional stereoisomeric AUC relationships. Examples include:

R-oxybutynin to S-oxybutynin at approximately 0.7:1.
R-N-desethyloxybutynin to R-oxybutynin from approximately 0.4:1 to 1.6:1.
R-N-desethyloxybutynin to S-N-desethyloxybutynin from approximately 0.5:1 to 1.3:1.

These claims are narrower and more dependent on validated bioanalytical methods. They may be difficult to enforce without access to a competitor’s clinical pharmacokinetic data.

Peak plasma concentration limitations

Claims 12, 13, 26, 27 and 39 to 43 impose peak metabolite concentration limits:

Claims	N-desethyloxybutynin peak concentration
12, 26	Less than about 8 ng/mL
13, 27	Less than about 5 ng/mL
39	About 0.5 to 8 ng/mL
41	About 1.0 to 3 ng/mL
43	About 3 ng/mL

Claims 56 to 58 focus on R-N-desethyloxybutynin, including a peak concentration below approximately 4 ng/mL, a range of approximately 0.25 to 4 ng/mL, and a target of approximately 1.5 ng/mL.

Time-course limitations

Claims 48 to 53 impose post-administration concentration limits:

Oxybutynin below approximately 2.0 ng/mL at six hours.
N-desethyloxybutynin below approximately 2.0 ng/mL at six hours.
Both compounds below approximately 8 ng/mL at 24 hours.
Concentrations below approximately 8 ng/mL during steady state.
Administration for approximately 24 to 96 hours.

These limitations are especially relevant to delivery systems using sustained transdermal release, multi-day application, or controlled absorption.

Permeation-enhancer limitations

Claims 29, 30, 34 and 35 address the formulation component. Claim 29 lists:

Fatty acids
Fatty acid esters
Fatty alcohols
Fatty acid esters of lactic acid or glycolic acid
Glycerol triesters, diesters and monoesters
Triacetin
Short-chain alcohols
Mixtures of those materials

Claim 30 specifically identifies triacetin. The corresponding article-of-manufacture claims are 34 and 35.

The permeation-enhancer claims are narrow relative to the independent claims because the independent claims do not require any enhancer. A competing product could avoid these dependent claims by using a different enhancer or by relying on passive permeation, while still potentially falling within claim 1 or claim 15 if the AUC limitations were met.

What formulations are protected by US 7,029,694?

The patent protects topical oxybutynin gel formulations only when they satisfy the claimed pharmacokinetic conditions. The claims do not broadly cover every oxybutynin gel.

Potentially covered products include:

Racemic oxybutynin gel.
R-oxybutynin gel.
S-oxybutynin gel.
Gel containing triacetin.
Gel containing another listed permeation enhancer.
Multi-day transdermal gel producing the specified oxybutynin and metabolite exposure.
Products with reduced N-desethyloxybutynin peak concentrations.

A formulation patent typically focuses on composition. This patent instead links the composition to the biological result produced after administration. That structure narrows literal claim scope but can complicate design-around analysis because the relevant evidence may reside in clinical pharmacology data rather than the product label.

What adverse effects does the patent address?

Claim 14 and claim 28 identify the adverse drug experiences the invention seeks to minimize:

Gastrointestinal or genitourinary effects
Nervous-system effects
Cardiovascular effects
Dermatological effects
Ophthalmic effects

The patent’s technical premise is that oral oxybutynin undergoes substantial first-pass metabolism, producing N-desethyloxybutynin. Transdermal delivery reduces first-pass exposure and can alter the relative plasma exposure of oxybutynin and its metabolite.

The adverse-effect language is a claim element, but it may not require proof that a particular patient actually experienced an adverse event. In a method claim, the issue is likely whether the treatment is administered under conditions that achieve the claimed pharmacokinetic profile and are intended to minimize the specified effects. Claim construction would depend on the patent specification, prosecution history, and the governing court’s interpretation of “minimizing.”

How strong is the patent estate for oxybutynin gel?

The estate was historically stronger as a layered portfolio than as a single patent.

Protection category	Relevance to US 7,029,694
Oxybutynin compound	Not the focus
Transdermal delivery	Directly relevant
Topical gel composition	Relevant, but only with the claimed pharmacokinetic result
Permeation enhancer	Narrow dependent-claim protection
Pharmacokinetic profile	Core protection
Stereoisomer ratios	Narrow, technically specific protection
Method of treating overactive bladder	Covered through the PK-limited method claims
Article of manufacture	Covered through claims 15 to 28 and related dependents
Manufacturing process	Not materially covered by the supplied claims
Device or patch structure	Not materially covered by the supplied claims

The patent’s principal strength was the combination of delivery route, therapeutic indication and measurable pharmacokinetic relationship. Its principal weakness was that infringement required proof of biological results that may vary with dose, application site, skin condition, sampling protocol, assay method and patient population.

When did US Patent 7,029,694 lose exclusivity?

The patent was granted April 18, 2006. The underlying application was filed in 2003, with an earlier priority date reflected in the patent family. On a nominal 20-year term from the nonprovisional filing date, the patent term ended in 2023, subject to patent-term adjustment.

A definitive expiration date must be taken from the USPTO Patent Center record, including:

Patent-term adjustment.
Terminal disclaimers.
Maintenance-fee status.
Any patent-term extension under 35 U.S.C. §156.
Any correction or reexamination affecting the term.

The patent does not appear to be a current long-duration exclusivity barrier in 2025. Its claims remain relevant for historical litigation, prosecution, freedom-to-operate analysis and interpretation of the Gelnique patent portfolio, but an expired patent generally cannot support a new US infringement action for conduct occurring after expiration.

What was the Orange Book status of US 7,029,694?

US 7,029,694 was associated with the oxybutynin topical gel product Gelnique, marketed for overactive bladder. The FDA Orange Book historically listed patents for approved oxybutynin gel products, including formulation and method-of-use patents associated with the product’s NDA.

The relevant regulatory framework was:

NDA approval for Gelnique.
Orange Book patent listing under the approved oxybutynin gel product.
Potential Paragraph IV certifications by abbreviated new drug applicants.
Possible 30-month stays if a listed patent was timely asserted.

Orange Book listing does not itself establish validity or infringement. It creates a regulatory pathway for generic applicants to make Paragraph IV certifications and can trigger patent litigation under the Hatch-Waxman Act.

Because Orange Book listings can change after patent expiration, delisting, or product-status changes, the current FDA listing should be evaluated by NDA and patent number rather than by relying only on historical product references. [FDA, 2024]

Which companies challenged or competed with oxybutynin gel?

The relevant competitive field included:

Watson Pharmaceuticals, later Actavis, associated with Gelnique.
Generic drug applicants seeking approval for oxybutynin gel.
Manufacturers of alternative oxybutynin dosage forms.
Manufacturers of oxybutynin transdermal patches.
Manufacturers of oral extended-release oxybutynin.
Manufacturers of other overactive-bladder therapies, including antimuscarinic and beta-3 agonist products.

The principal commercial alternatives were:

Product type	Commercial and patent significance
Oral immediate-release oxybutynin	Older, lower-barrier dosage form with greater first-pass metabolism
Oral extended-release oxybutynin	Competes on dosing convenience and exposure control
Transdermal oxybutynin patch	Competes on reduced gastrointestinal exposure and delivery technology
Oxybutynin topical gel	Direct product category implicated by US 7,029,694
Non-oxybutynin antimuscarinics	Therapeutic substitutes
Mirabegron and other beta-3 agonists	Pharmacologically distinct substitutes

Biosimilar risk is not relevant. Oxybutynin is a small-molecule drug, so the relevant competition is generic substitution under the ANDA pathway, not biosimilar approval under the Biologics Price Competition and Innovation Act.

What Paragraph IV and generic-entry risks existed?

A generic oxybutynin gel applicant would typically evaluate four risks:

Whether the proposed gel produces the claimed oxybutynin-to-metabolite AUC ratio.
Whether the product’s label directs treatment for overactive bladder.
Whether the formulation practices a listed permeation-enhancer claim.
Whether the patent remained unexpired when the ANDA litigation was filed.

A Paragraph IV challenge could attack the patent on:

Anticipation.
Obviousness.
Lack of written description.
Lack of enablement.
Indefiniteness of “about,” “minimizing,” or “approximately equal.”
Insufficient support for the full AUC and peak-concentration ranges.
Non-infringement based on a different PK profile.

The most effective design-around would generally target the pharmacokinetic limitation. A generic product that uses the same therapeutic route but does not produce the claimed AUC relationship may avoid literal infringement. That strategy must account for potential doctrine-of-equivalents arguments and for any separate composition or formulation patents in the broader portfolio.

What litigation and settlement issues are most important?

The supplied claims do not establish a complete litigation history. The relevant disputes would likely involve:

ANDA filings for oxybutynin gel.
Patent-listing status under the Orange Book.
Paragraph IV notices.
Hatch-Waxman infringement actions under 35 U.S.C. §271(e)(2).
Thirty-month stays.
Generic launch dates following settlement or court judgment.
Whether the asserted claims were method claims, product claims, or both.

Settlement agreements may have included licensed entry dates, authorized-generic arrangements, or restrictions tied to other patents in the oxybutynin portfolio. A definitive settlement analysis requires the individual district-court dockets, FDA patent certifications and any FTC-filed agreement records. The supplied patent claims alone do not establish the existence or terms of a settlement.

What are the principal validity risks?

Written description and enablement

The claims cover broad numerical ranges across racemic and enantiomeric forms, multiple metabolites and multiple clinical exposure metrics. A challenger could argue that the specification did not adequately demonstrate the full scope of the ranges.

Indefiniteness

Potential targets include:

“About”
“Approximately equal”
“Minimizing”
“Adverse drug experience”
“For the duration of administration”

These terms may be defensible if the specification supplies objective boundaries and examples, but the risk increases when the claims depend on variable clinical measurements.

Obviousness

A challenger could combine:

Known oxybutynin transdermal delivery.
Known reduction of first-pass metabolism.
Known N-desethyloxybutynin pharmacology.
Routine pharmacokinetic optimization.

The patentee’s strongest response would be evidence of an unexpected relationship between transdermal administration, metabolite suppression and reduced adverse effects.

Claim-construction risk

The method claims combine intent, treatment outcome and measurable pharmacokinetic limitations. Courts may treat the AUC requirement as a strict limitation. The article-of-manufacture claims similarly require that the product produce the stated result upon administration.

How does US 7,029,694 compare with ordinary oxybutynin formulation patents?

US 7,029,694 is narrower than a broad formulation patent but potentially more difficult to clear through routine formulation review.

A conventional formulation claim may be avoided by changing:

Polymer system.
Solvent.
Drug concentration.
Enhancer.
Container or applicator.
Release-control mechanism.

The claims here may still apply after those changes if the resulting product produces the claimed plasma profile. Conversely, a product using a similar gel base may avoid the patent if its pharmacokinetics fall outside the claimed ranges.

This creates a two-part freedom-to-operate analysis:

Composition and formulation claims in the wider patent family.
Pharmacokinetic and treatment claims in US 7,029,694.

Key Takeaways

US 7,029,694 centered on topical oxybutynin gel for overactive bladder.
Its principal limitation was an oxybutynin-to-N-desethyloxybutynin plasma AUC ratio, generally about 0.5:1 to 5:1.
The claims also covered peak metabolite concentrations, stereoisomer ratios, multi-day administration and selected permeation enhancers.
Claims 1 and 15 were the principal method and article-of-manufacture claims.
The patent addressed reduced anticholinergic or antimuscarinic adverse effects associated with oral oxybutynin.
It did not cover every oxybutynin gel independently of pharmacokinetic performance.
Biosimilar risk was irrelevant because oxybutynin is a small molecule.
Generic risk historically arose through the ANDA and Paragraph IV framework.
The nominal patent term appears to have ended in 2023, subject to the USPTO’s final term calculation.
Current commercial clearance depends more heavily on other oxybutynin formulation, delivery and use patents than on this patent if its term has expired.

FAQs About US Patent 7,029,694

Does US Patent 7,029,694 cover oral oxybutynin?

No. The independent claims require administration as a topical gel or an article of manufacture comprising a topical gel.

Does the patent cover oxybutynin patches?

Not on the supplied claims alone. A patch could potentially be outside the claims because the claims expressly require a topical gel, although separate patents may cover transdermal patches or related delivery systems.

Is N-desethyloxybutynin the key metabolite in the claims?

Yes. Claims 5, 6, 19, 20 and numerous later claims expressly identify N-desethyloxybutynin, including its R and S enantiomers.

Can a generic avoid the patent by changing the permeation enhancer?

Changing the enhancer may avoid claims 29, 30, 34 and 35, but it would not necessarily avoid claims 1 or 15. The product would still need to be evaluated against the AUC and plasma-concentration limitations.

Is the patent still a current barrier to a US generic launch?

The patent’s nominal term appears to have ended in 2023, subject to the USPTO term record. Current launch risk therefore depends on any remaining term adjustment, regulatory listing, litigation order and other patents covering oxybutynin gel.

References

U.S. Patent No. 7,029,694. (2006). Methods and compositions for treating overactive bladder. U.S. Patent and Trademark Office. https://patents.google.com/patent/US7029694
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (2009). Gelnique NDA approval materials and prescribing information. FDA. https://www.accessdata.fda.gov/
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure. https://www.uspto.gov/web/offices/pac/mpep/

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	488233	⤷ Start Trial
Australia	2001253782	⤷ Start Trial
Australia	2003287377	⤷ Start Trial
Australia	2003294239	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,029,694

Summary for Patent: 7,029,694